PE20212157A1 - Composiciones farmaceuticas que comprenden meloxicam - Google Patents
Composiciones farmaceuticas que comprenden meloxicamInfo
- Publication number
- PE20212157A1 PE20212157A1 PE2021001288A PE2021001288A PE20212157A1 PE 20212157 A1 PE20212157 A1 PE 20212157A1 PE 2021001288 A PE2021001288 A PE 2021001288A PE 2021001288 A PE2021001288 A PE 2021001288A PE 20212157 A1 PE20212157 A1 PE 20212157A1
- Authority
- PE
- Peru
- Prior art keywords
- meloxicam
- migraine
- rizatriptan
- pain
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802198P | 2019-02-06 | 2019-02-06 | |
| US201962803756P | 2019-02-11 | 2019-02-11 | |
| US201962835613P | 2019-04-18 | 2019-04-18 | |
| US201962846311P | 2019-05-10 | 2019-05-10 | |
| US201962860705P | 2019-06-12 | 2019-06-12 | |
| US201962895933P | 2019-09-04 | 2019-09-04 | |
| US201962895956P | 2019-09-04 | 2019-09-04 | |
| US201962955905P | 2019-12-31 | 2019-12-31 | |
| PCT/US2020/017046 WO2020163620A1 (en) | 2019-02-06 | 2020-02-06 | Pharmaceutical compositions comprising meloxicam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212157A1 true PE20212157A1 (es) | 2021-11-09 |
Family
ID=71947112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001288A PE20212157A1 (es) | 2019-02-06 | 2020-02-06 | Composiciones farmaceuticas que comprenden meloxicam |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3920909A4 (ja) |
| JP (3) | JP7237386B2 (ja) |
| KR (1) | KR20210118880A (ja) |
| CN (1) | CN113423397A (ja) |
| AU (2) | AU2020218253B2 (ja) |
| BR (1) | BR112021015467A2 (ja) |
| CA (2) | CA3213549A1 (ja) |
| CL (1) | CL2021002070A1 (ja) |
| CO (1) | CO2021010380A2 (ja) |
| CR (1) | CR20210420A (ja) |
| EC (1) | ECSP21060962A (ja) |
| IL (1) | IL285389A (ja) |
| MA (1) | MA54904A (ja) |
| MX (1) | MX2021009435A (ja) |
| PE (1) | PE20212157A1 (ja) |
| SG (1) | SG11202107926XA (ja) |
| WO (1) | WO2020163620A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116887838A (zh) * | 2020-12-31 | 2023-10-13 | 艾克萨姆治疗公司 | 包含美洛昔康的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2234324T3 (es) * | 1998-11-02 | 2005-06-16 | MERCK & CO., INC. | Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña. |
| US20040214861A1 (en) * | 2003-03-28 | 2004-10-28 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine |
| US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US20090068262A1 (en) * | 2007-04-04 | 2009-03-12 | Ilan Zalit | Rapid dissolution of combination products |
| KR101743591B1 (ko) * | 2009-05-13 | 2017-06-20 | 사이덱스 파마슈티칼스, 인크. | 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법 |
| US9821075B2 (en) * | 2015-02-10 | 2017-11-21 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| KR102465027B1 (ko) * | 2015-02-10 | 2022-11-09 | 액섬 테라퓨틱스, 인크. | 멜록시캄을 포함하는 약학 조성물 |
| WO2018055574A1 (en) * | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| PT3565550T (pt) * | 2017-01-04 | 2021-01-20 | Axsome Therapeutics Inc | Composições farmacêuticas compreendendo meloxicam e rizatriptano |
| US10471014B2 (en) * | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| NZ758664A (en) * | 2017-05-10 | 2022-08-26 | Axsome Therapeutics Inc | Pharmaceutical compositions comprising meloxicam |
-
2020
- 2020-02-06 CA CA3213549A patent/CA3213549A1/en active Pending
- 2020-02-06 CN CN202080012487.9A patent/CN113423397A/zh active Pending
- 2020-02-06 MA MA054904A patent/MA54904A/fr unknown
- 2020-02-06 CR CR20210420A patent/CR20210420A/es unknown
- 2020-02-06 JP JP2021545919A patent/JP7237386B2/ja active Active
- 2020-02-06 PE PE2021001288A patent/PE20212157A1/es unknown
- 2020-02-06 CA CA3128940A patent/CA3128940C/en active Active
- 2020-02-06 WO PCT/US2020/017046 patent/WO2020163620A1/en active Application Filing
- 2020-02-06 AU AU2020218253A patent/AU2020218253B2/en active Active
- 2020-02-06 SG SG11202107926XA patent/SG11202107926XA/en unknown
- 2020-02-06 KR KR1020217026519A patent/KR20210118880A/ko not_active Application Discontinuation
- 2020-02-06 EP EP20752178.2A patent/EP3920909A4/en active Pending
- 2020-02-06 MX MX2021009435A patent/MX2021009435A/es unknown
- 2020-02-06 BR BR112021015467-1A patent/BR112021015467A2/pt unknown
-
2021
- 2021-08-04 IL IL285389A patent/IL285389A/en unknown
- 2021-08-05 CL CL2021002070A patent/CL2021002070A1/es unknown
- 2021-08-06 CO CONC2021/0010380A patent/CO2021010380A2/es unknown
- 2021-08-17 EC ECSENADI202160962A patent/ECSP21060962A/es unknown
-
2023
- 2023-02-21 JP JP2023025218A patent/JP7420990B2/ja active Active
- 2023-04-27 AU AU2023202545A patent/AU2023202545A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002855A patent/JP2024026732A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP21060962A (es) | 2021-11-30 |
| CR20210420A (es) | 2021-12-22 |
| EP3920909A4 (en) | 2022-11-30 |
| JP2024026732A (ja) | 2024-02-28 |
| AU2023202545A1 (en) | 2023-05-18 |
| AU2020218253A1 (en) | 2021-08-12 |
| EP3920909A1 (en) | 2021-12-15 |
| IL285389A (en) | 2021-09-30 |
| JP2023062144A (ja) | 2023-05-02 |
| BR112021015467A2 (pt) | 2021-10-05 |
| CO2021010380A2 (es) | 2021-09-30 |
| JP7420990B2 (ja) | 2024-01-23 |
| CN113423397A (zh) | 2021-09-21 |
| SG11202107926XA (en) | 2021-08-30 |
| WO2020163620A1 (en) | 2020-08-13 |
| CA3128940C (en) | 2023-11-07 |
| AU2020218253B2 (en) | 2023-02-23 |
| JP7237386B2 (ja) | 2023-03-13 |
| MA54904A (fr) | 2021-12-15 |
| CA3128940A1 (en) | 2020-08-13 |
| CL2021002070A1 (es) | 2022-04-01 |
| CA3213549A1 (en) | 2020-08-13 |
| MX2021009435A (es) | 2021-09-10 |
| JP2022519670A (ja) | 2022-03-24 |
| KR20210118880A (ko) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
| CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EA200701195A1 (ru) | Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением | |
| CL2018000811A1 (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
| ECSP19014247A (es) | Formas de dosificación para tratar y prevenir trastornos del sueño | |
| MX2021002322A (es) | Nuevos metodos. | |
| CL2008003201A1 (es) | Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno. | |
| BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
| BR112022010319A2 (pt) | Uso de bi853520 no tratamento de câncer | |
| BR112017006406A2 (pt) | composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico | |
| CL2020003010A1 (es) | Moduladores de la expresión de apol1 | |
| ECSP21060962A (es) | Composiciones farmacéuticas que comprenden meloxicam | |
| ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| MA39443A1 (fr) | Nouvelle formulation de méloxicam | |
| MX2010010334A (es) | Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida. | |
| CO2020004034A2 (es) | Métodos para el tratamiento de distrofia muscular | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| MX2024003772A (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| BR112014030777A2 (pt) | método e composição para aliviar sintomas de tumor | |
| CL2020000859A1 (es) | Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas. | |
| MX2018015208A (es) | Andrografolido para tratar formas progresivas de esclerosis multiple. | |
| MX2021003651A (es) | Formulacion que comprende aceite ozonizado en el tratamiento de un tumor. | |
| BR112021010856A2 (pt) | Vibegron para o tratamento de sintomas de bexiga hiperativa | |
| AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño |